<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Heparin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01109</strong>&#160; (APRD00056)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin <span class="caps">III</span> (<span class="caps">ATIII</span>) and greatly accelerates the rate at which <span class="caps">ATIII</span> inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (<span class="caps">LMWH</span>) in the following ways: the average molecular weight of <span class="caps">LMWH</span> is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than <span class="caps">LMWH</span> for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01109/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01109/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01109.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01109.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01109.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01109.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01109.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01109">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Eparina</td><td>Italian</td><td>DCIT</td></tr><tr><td>Heparinate</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Heparinic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Heparin sodium</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000417/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000417/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000417">DBSALT000417</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Calcilean</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Calciparine</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Hepalean</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Heparin LEO</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Heparin Lock Flush</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Liquaemin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Liquemin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Multiparin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Novoheparin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/fibrinolytic-agents">Fibrinolytic Agents</a></li>
<li><a href="/mesh/anticoagulants">Anticoagulants</a></li>
<li><a href="/mesh/heparins">Heparins</a></li></ul></td></tr><tr><th>CAS number</th><td>9005-49-6</td></tr><tr><th>Weight</th><td>Average: <br>Monoisotopic: </td></tr><tr><th>Chemical Formula</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>InChI Key</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>InChI</th><td><div class="wrap"></div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap"></div></td></tr><tr><th>SMILES</th><td><div class="wrap"></div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Superclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Class</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Unfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension, prevention of post-operative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery. In cardiology, it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin therapy in patients with unstable angina and/or non-Q wave myocardial infarctions (i.e. non-ST elevated acute coronary artery syndrome) who are on platelet glycoprotein (IIb/IIIa) receptor inhibitors. Additionally, it is used to prevent clotting during dialysis and surgical procedures, maintain the patency of intravenous injection devices and prevent in vitro coagulation of blood transfusions and in blood samples drawn for laboratory values.</td></tr><tr><th>Pharmacodynamics</th><td>Unfractionated heparin is a highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from 3000 to 30,000 daltons. Heparin is obtained from liver, lung, mast cells, and other cells of vertebrates. Heparin is a well-known and commonly used anticoagulant which has antithrombotic properties. Heparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo. Small amounts of heparin in combination with antithrombin III, a heparin cofactor,) can inhibit thrombosis by inactivating Factor Xa and thrombin. Once active thrombosis has developed, larger amounts of heparin can inhibit further coagulation by inactivating thrombin and preventing the conversion of fibrinogen to fibrin. Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. Heparin prolongs several coagulation tests. Of all the coagulation tests, activated partial prothrombin time (aPTT) is the most clinically important value.</td></tr><tr><th>Mechanism of action</th><td>Under normal circumstances, antithrombin III (ATIII) inactivates thrombin (factor IIa) and factor Xa. This process occurs at a slow rate. Administered heparin binds reversibly to ATIII and leads to almost instantaneous inactivation of factors IIa and Xa The heparin-ATIII complex can also inactivate factors IX, XI, XII and plasmin. The mechanism of action of heparin is ATIII-dependent. It acts mainly by accelerating the rate of the neutralization of certain activated coagulation factors by antithrombin, but other mechanisms may also be involved. The antithrombotic effect of heparin is well correlated to the inhibition of factor Xa. Heparin is not a thrombolytic or fibrinolytic. It prevents progression of existing clots by inhibiting further clotting. The lysis of existing clots relies on endogenous thrombolytics.</td></tr><tr><th>Absorption</th><td>Heparin must be given parenterally as it is not absorbed through the gastrointestinal mucosa. It is usually given by iv infusion or deep sc injection. The onset of action is immediate after iv injection but can be delayed 20 to 60 minutes following sc injection.

Plasma heparin concentrations may be increased and activated partial thromboplastin times (aPTTs) may be more prolonged in geriatric adults (older than 60 years of age) compared with younger adults.</td></tr><tr><th>Volume of distribution</th><td><p>40-70 mL/min (approximately the same as blood volume)<br>
Although heparin does not distribute into adipose tissues, clinicians should use actual body weight in obese patients to account for extra vasculature.</p></td></tr><tr><th>Protein binding</th><td>Very high, mostly to low-density lipoproteins. It is also extensively bound by globulins and fibrinogens.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Liver and the reticulo-endothelial system are the sites of biotransformation. The metabolic fate of heparin is not well understood. </p></td></tr><tr><th>Route of elimination</th><td>The drug appears to be removed mainly by the reticuloendothelial system. A small fraction of unchanged heparin also appears to be excreted in urine. Heparin cannot be eliminated by hemodialysis.</td></tr><tr><th>Half life</th><td>1.5 hours. 

The plasma half-life of heparin increases from about 60 minutes with a 100 unit/kg dose to about 150 minutes with a 400 unit/kg dose. </td></tr><tr><th>Clearance</th><td><p>Adult Clearance = 0.43 ml/kg/min<br>
25-28 weeks gestation = 1.49 ml/kg/min</p></td></tr><tr><th>Toxicity</th><td>In mouse, the median lethal dose is greater than 5000 mg/kg. Another side effect is heparin-induced thrombocytopenia (HIT syndrome). Platelet counts usually do not fall until between days 5 and 12 of heparin therapy. HIT is caused by an immunological reaction that makes platelets form clots within the blood vessels, thereby using up coagulation factors. It can progress to thrombotic complications such as arterial thrombosis, gangrene, stroke, myocardial infarction and disseminated intravascular coagulation. Symptoms of overdose may show excessive prolongation of aPTT or by bleeding, which may be internal or external, major or minor. Therapeutic doses of heparin give for at least 4 months have been associated with osteoporosis and spontaneous vertebral fractures. Osteoporosis may be reversible once heparin is discontinued. Although a causal relationship has not been established, administration of injections preserved with benzyl alcohol has been associated with toxicity in neonates. Toxicity appears to have resulted from administration of large amounts (i.e., about 100&#8211;400 mg/kg daily) of benzyl alcohol in these neonates. Its use is principally associated with the use of bacteriostatic 0.9% sodium chloride intravascular flush or endotracheal tube lavage solutions.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th><th>SMPDB ID</th></tr></thead><tbody><tr><td>Heparin Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00274?highlight%5Bcompounds%5D%5B%5D=DB01109&amp;highlight%5Bproteins%5D%5B%5D=DB01109">SMP00274</a></td></tr><tr><td>Fc Epsilon Receptor I Signaling in Mast Cells</td><td>Signaling</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00358?highlight%5Bcompounds%5D%5B%5D=DB01109&amp;highlight%5Bproteins%5D%5B%5D=DB01109">SMP00358</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          <span class="wishart wishart-not-available">Not Available</span> 
        </td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          <span class="wishart wishart-not-available">Not Available</span> 
        </td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          <span class="wishart wishart-not-available">Not Available</span> 
        </td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          <span class="wishart wishart-not-available">Not Available</span> 
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          <span class="wishart wishart-not-available">Not Available</span> 
        </td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          <span class="wishart wishart-not-available">Not Available</span> 
        </td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Sanofi aventis us llc</li>
<li>Hospira inc</li>
<li>International medication systems ltd</li>
<li>Luitpold pharmaceuticals inc</li>
<li>Parke davis div warner lambert co</li>
<li>Smith and nephew solopak div smith and nephew</li>
<li>Solopak medical products inc</li>
<li>Abraxis pharmaceutical products</li>
<li>Akorn inc</li>
<li>App pharmaceuticals llc</li>
<li>Baxter healthcare corp anesthesia and critical care</li>
<li>Baxter healthcare corp anesthesia critical care</li>
<li>Chamberlin parenteral corp</li>
<li>Dell laboratories inc</li>
<li>Eli lilly and co</li>
<li>Marsam pharmaceuticals llc</li>
<li>Organon usa inc</li>
<li>Pharmaceutical specialist assoc</li>
<li>Pharmacia and upjohn co</li>
<li>Sagent pharmaceuticals inc</li>
<li>Watson laboratories inc</li>
<li>Baxter healthcare corp</li>
<li>Mcgaw inc</li>
<li>B braun medical inc</li>
<li>Pharma serve inc sub torigian laboratories</li>
<li>3m pharmaceuticals inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.amsinomedusa.com">Amsino Medical Usa</a></li>
<li><a href="http://www.apppharma.com">APP Pharmaceuticals</a></li>
<li><a href="http://www.bbraun.com">B. Braun Melsungen AG</a></li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.bd.com">Becton Dickinson</a></li>
<li>Bioiberica Sa</li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.eisai.com">Eisai Inc.</a></li>
<li><a href="http://www.giv.com">General Injectables and Vaccines Inc.</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li>Mason Distributors</li>
<li><a href="http://www.medefil.com">Medefil Inc.</a></li>
<li>Medical Techniques LLC</li>
<li>Neuman Distributors Inc.</li>
<li><a href="http://www.pfizer.com">Pfizer Inc.</a></li>
<li><a href="http://www.pharmaciaupjohn.com">Pharmacia Inc.</a></li>
<li><a href="http://www.sagentpharma.com">Sagent Pharmaceuticals</a></li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.spectrumpharm.com">Spectrum Pharmaceuticals</a></li>
<li><a href="http://www.tycohealthcare.co.uk">Tyco Healthcare Group LP</a></li>
<li><a href="http://www.vetter-pharma.com">Vetter Pharma Fertigung GmbH and Co. KG</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Liquid</td><td>Intravenous</td><td></td></tr><tr><td>Liquid</td><td>Irrigation</td><td></td></tr><tr><td>Solution</td><td>Intraperitoneal</td><td></td></tr><tr><td>Solution</td><td>Intravenous</td><td></td></tr><tr><td>Solution</td><td>Subcutaneous</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Heparin sod 1000000 unit powder</td><td>1318.63USD</td><td>each</td></tr><tr><td>Heparin sod 100000 unit powder</td><td>256.73USD</td><td>each</td></tr><tr><td>Heparin Sodium (Porcine) 1000 unit/ml Solution 10ml Vial</td><td>188.99USD</td><td>vial</td></tr><tr><td>Heparin sod 25000 unit powder</td><td>58.8USD</td><td>each</td></tr><tr><td>Heparin Sodium (Porcine) 10000 unit/ml Solution 5ml Vial</td><td>29.99USD</td><td>vial</td></tr><tr><td>Heparin Sodium (Porcine) 10000 unit/ml vial</td><td>10.37USD</td><td>vial</td></tr><tr><td>Hep-lock flush 100 unit/ml kit</td><td>10.08USD</td><td>kit</td></tr><tr><td>Hep-lock flush 10 unit/ml kit</td><td>8.91USD</td><td>kit</td></tr><tr><td>Heparin Leo 25000 unit/ml</td><td>8.42USD</td><td>ml</td></tr><tr><td>Heparin sod 1000 unit/ml vial</td><td>7.92USD</td><td>ml</td></tr><tr><td>Heparin sod 5000 unit/ml syringe</td><td>3.08USD</td><td>ml</td></tr><tr><td>Heparin iv flush 100 unit/ml</td><td>2.71USD</td><td>ml</td></tr><tr><td>Hepalean 10000 unit/ml</td><td>2.32USD</td><td>ml</td></tr><tr><td>Heparin Leo 10000 unit/ml</td><td>2.03USD</td><td>ml</td></tr><tr><td>Heparin lock flush 10 unit/ml</td><td>1.21USD</td><td>ml</td></tr><tr><td>Heparin lock flush 100 unit/ml</td><td>1.13USD</td><td>ml</td></tr><tr><td>Hep-lock u-p 10 unit/ml vial</td><td>0.98USD</td><td>ml</td></tr><tr><td>Hepalean 1000 unit/ml</td><td>0.98USD</td><td>ml</td></tr><tr><td>Hep-lock u-p 100 unit/ml vial</td><td>0.96USD</td><td>ml</td></tr><tr><td>Heparin Leo 1000 unit/ml</td><td>0.43USD</td><td>ml</td></tr><tr><td>Heparin Leo 100 unit/ml Lock Flush</td><td>0.36USD</td><td>ml</td></tr><tr><td>Heparin Lock Flush 100 unit/ml Lock Flush</td><td>0.3USD</td><td>ml</td></tr><tr><td>Heparin Lock Flush 10 unit/ml Lock Flush</td><td>0.29USD</td><td>ml</td></tr><tr><td>Heparin iv flush 1 unit/ml syr</td><td>0.19USD</td><td>ml</td></tr><tr><td>Heparin iv flush 2 unit/ml syr</td><td>0.19USD</td><td>ml</td></tr><tr><td>Heparin lock 100 unit/ml vial</td><td>0.13USD</td><td>ml</td></tr><tr><td>Heparin lock 10 unit/ml vial</td><td>0.1USD</td><td>ml</td></tr><tr><td>Heparin-1/2ns 25000 unit/250</td><td>0.03USD</td><td>ml</td></tr><tr><td>Heparin-1/2ns 12500 unit/250</td><td>0.02USD</td><td>ml</td></tr><tr><td>Heparin-ns 2000 unit/1000 ml</td><td>0.01USD</td><td>ml</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>water solubility</td><td>Soluble</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>logP</td><td>-13.2</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Fernando Fussi, Gianfranco Fedeli, &#8220;Oligo-heteropolysaccharides having a heparin-like activity method for their preparation and pharmaceutical compositions based thereon.&#8221; U.S. Patent US4757057, issued June, 1952.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=4757057&amp;tbm=pts" target="_blank">US4757057 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Linhardt RJ, Gunay NS: Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost. 1999;25 Suppl 3:5-16. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10549711">Pubmed</a></li>
	<li>Ferro DR, Provasoli A, Ragazzi M, Casu B, Torri G, Bossennec V, Perly B, Sinay P, Petitou M, Choay J: Conformer populations of L-iduronic acid residues in glycosaminoglycan sequences. Carbohydr Res. 1990 Jan 15;195(2):157-67. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2331699">Pubmed</a></li>
	<li>Mulloy B, Forster MJ, Jones C, Davies DB: N.m.r. and molecular-modelling studies of the solution conformation of heparin. Biochem J. 1993 Aug 1;293 ( Pt 3):849-58. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8352752">Pubmed</a></li>
	<li>Hirsh J, Raschke R: Heparin and low-molecular-weight heparin: the Seventh <span class="caps">ACCP</span> Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3 Suppl):188S-203S. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15383472">Pubmed</a></li>
	<li>Petitou M, Herault JP, Bernat A, Driguez PA, Duchaussoy P, Lormeau JC, Herbert JM: Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature. 1999 Apr 1;398(6726):417-22. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10201371">Pubmed</a></li>
	<li>American Academy of Pediatrics Committee on Fetus and Newborn and Committee on Drugs. Benzyl alcohol: toxic agent in neonatal units. Pediatrics. 1983; 72:356-8. [PubMed] [<span class="caps">IDIS</span> 175725]</li>
	<li>Anon. Benzyl alcohol may be toxic to newborns. <span class="caps">FDA</span> Drug Bull. 1982; 12:10-1. [PubMed]</li>
	<li>Anon. Neonatal deaths associated with use of benzyl alcohol&#8212;United States. <span class="caps">MMWR</span> Morb Mortal Wkly Rep. 1982; 31:290-1. [PubMed] [<span class="caps">IDIS</span> 150868]</li>
	<li>Abbott Laboratories. Heparin lock flush solution, <span class="caps">USP</span> 100 <span class="caps">USP</span> units/mL prescribing information. North Chicago, IL; 1998 Jul.</li>
	<li>Spruill WJ, Wade WE, Huckaby WG, Leslie RB: Achievement of anticoagulation by using a weight-based heparin dosing protocol for obese and nonobese patients. Am J Health Syst Pharm. 2001 Nov 15;58(22):2143-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11760916">Pubmed</a></li>
	<li>McDonald MM, Jacobson LJ, Hay WW Jr, Hathaway WE: Heparin clearance in the newborn. Pediatr Res. 1981 Jul;15(7):1015-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7254945">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C00374" target="_blank">C00374 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46507594" target="_blank">46507594 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.751.html" target="_blank">751 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=28304" target="_blank">28304 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1909300" target="_blank">CHEMBL1909300 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000189" target="_blank">DAP000189 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA449855" target="_blank">PA449855 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=453781" target="_blank">453781 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic/heparin.htm" target="_blank">http://www.rxlist.com/cgi/generic/heparin.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/heparin.html" target="_blank">http://www.drugs.com/heparin.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Heparin" target="_blank">Heparin <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>C05BA01<ul class="atc-drug-tree"><li><a href="/atc/C#C">C &#8212; CARDIOVASCULAR SYSTEM</a></li><li><a href="/atc/C05#C05">C05 &#8212; VASOPROTECTIVES</a></li><li><a href="/atc/C05B#C05B">C05B &#8212; ANTIVARICOSE THERAPY</a></li><li><a href="/atc/C05BA#C05BA">C05BA &#8212; Heparins or heparinoids for topical use</a></li></ul>C05BA03<ul class="atc-drug-tree"><li><a href="/atc/C#C">C &#8212; CARDIOVASCULAR SYSTEM</a></li><li><a href="/atc/C05#C05">C05 &#8212; VASOPROTECTIVES</a></li><li><a href="/atc/C05B#C05B">C05B &#8212; ANTIVARICOSE THERAPY</a></li><li><a href="/atc/C05BA#C05BA">C05BA &#8212; Heparins or heparinoids for topical use</a></li></ul>S01XA09<ul class="atc-drug-tree"><li><a href="/atc/S#S">S &#8212; SENSORY ORGANS</a></li><li><a href="/atc/S01#S01">S01 &#8212; OPHTHALMOLOGICALS</a></li><li><a href="/atc/S01X#S01X">S01X &#8212; OTHER OPHTHALMOLOGICALS</a></li><li><a href="/atc/S01XA#S01XA">S01XA &#8212; Other ophthalmologicals</a></li></ul>S01XA14<ul class="atc-drug-tree"><li><a href="/atc/S#S">S &#8212; SENSORY ORGANS</a></li><li><a href="/atc/S01#S01">S01 &#8212; OPHTHALMOLOGICALS</a></li><li><a href="/atc/S01X#S01X">S01X &#8212; OTHER OPHTHALMOLOGICALS</a></li><li><a href="/atc/S01XA#S01XA">S01XA &#8212; Other ophthalmologicals</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>20:12.04.16</li>
<li>92:00.00</li></ul></td></tr><tr><th>PDB Entries</th><td><ul><li><a class="wishart-link-out" href="http://www.rcsb.org/pdb/explore.do?structureId=1JVQ" target="_blank">1JVQ <span class="glyphicon glyphicon-new-window"> </span></a></li></ul></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB01109.pdf?1265922803">show</a>(198 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB01109.pdf?1265922741">show</a>(72.1 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00945">Acetylsalicylic acid</a></td><td>Increased risk of bleeding. </td></tr><tr><td><a href="/drugs/DB06692">Aprotinin</a></td><td>Aprotinin, in the presence of heparin, has been found to prolong the activated clotting time (ACT) as measured by a celite surface activation method. The kaolin activated clotting time appears to be much less affected.</td></tr><tr><td><a href="/drugs/DB05394">corticotropin-releasing factor</a></td><td>Contraindication: Heparin may enhance the adverse/toxic effect of Corticorelin. Significant hypotension and bradycardia have been previously attributed to this combination. Corticorelin prescribing information describes a case in which a patient experienced a substantial fall in blood pressure and heart rate, resulting in asystole and requiring resuscitation.</td></tr><tr><td><a href="/drugs/DB01395">Drospirenone</a></td><td>Heparin can increase risk of hyperkalemia for patients on drospirenone</td></tr><tr><td><a href="/drugs/DB00055">Drotrecogin alfa</a></td><td>The potential benefits of drotrecogin alfa should be weighed against an increased risk of bleeding in patients receiving therapeutic doses of heparin. Monitor for bleeding during concomitant therapy, and immediately stop infusion of drotrecogin if clinically important bleeding occurs. In patients receiving prophylactic heparin doses, consider continuing this during drotrecogin. </td></tr><tr><td><a href="/drugs/DB01381">Ginkgo biloba</a></td><td>Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00208">Ticlopidine</a></td><td>Increased bleeding risk. Monitor aPTT.</td></tr><tr><td><a href="/drugs/DB00684">Tobramycin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Heparin. Monitor for increased bleeding during concomitant thearpy. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Adequate calcium intake is recommended, needs increased with long term use, supplement recommended.</li>
<li>Many herbs with anticoagulant properties (e.g. ginger, garlic, ginseng, green tea, evening primrose) may increase the risk of bleeding in patients on anticoagulant therapy such as heparin</li></ul></td></tr></tbody></table>